BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines reported new long-term survival data from the Phase 3 HERIZON-GEA-01 trial, with the TEVIMBRA plus ZIIHERA and chemotherapy regimen delivering median overall survival of 27.0 months in first-line HER2+ gastroesophageal cancer. After 35.3 months of follow-up, nearly 40% of patients on the TEVIMBRA-containing arm were alive at three years (39.8% 36-month OS), with an OS hazard ratio of 0.65 versus trastuzumab plus chemotherapy; the benefit held regardless of PD-L1 status.
Key figures
- Drug Name
- TEVIMBRA (tislelizumab) + ZIIHERA (zanidatamab)
- Phase Of Trial
- Phase 3
- Os 36 month pct
- 39.8%
- Os hazard ratio
- 0.65
- Median os months
- 27
- Pfs hazard ratio
- 0.61
- Median pfs months
- 12.7
- Patients randomized
- 914
- Trial followup months
- 35.3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.